The present invention is directed to 4′-substituted nucleoside derivatives of Formula I

##STR00001##

and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N.sup.4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N.sup.4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N.sup.4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

Disclosed herein are methods, compositions and kits for treating and inhibiting Poxviridae virus infections, for example, Vaccinia virus infections. Further disclosed are stop-gap methods for controlling the spread of Poxviridae virus infections.

Disclosed herein are methods, compositions and kits for treating and inhibiting Poxviridae virus infections, for example, Vaccinia virus infections. Further disclosed are stop-gap methods for controlling the spread of Poxviridae virus infections.